Turkish Study Brings Hope for Breast Cancer Treatment

The gene study of Turkish Scientist Professor Doctor Atilla Soran and his team, who live in the USA, which is accepted as one of the most important authorities in breast cancer, can open a new horizon in the treatment of breast cancer. With this study, hope may arise to halt the spread of breast cancer.

 

It can open new horizons

All over the world, rates of breast cancer and breast cancer death vary according to the region and ethnicity. In the USA, more than 300 thousand patients and 40 thousand deaths are expected due to breast cancer in 2020. When diagnosed early, the 5-year survival rate in breast cancer increases to 99 percent, while this rate decreases to 20 percent in those with late spread to organs. Stating that personalized treatments are planned using the next generation sequencing methods genetically today, University of Pittsburgh University Breast Surgery Department Clinical Research Director and Liv Hospital Ulus Consultant Physician Prof. Dr. Atilla Soran points out that their latest research may open new horizons in breast cancer treatment.

Personalized treatment with Next generation sequencing

Approximately 25 percent of patients with early stage breast cancer can have cancer re-spread after treatment. In advanced stage breast cancer that metastasizes, that is, spreading to organs, patients are treated with surgery, chemotherapy, hormonotherapy, immunotherapy and radiotherapy. Patients survive the problems caused by the side-effects of drugs or the spread of cancer. Today, personalized treatments are planned by using new generation sequencing methods.

The prestigious medical journal in the USA published the exciting research

University of Pittsburgh Medical Center Breast Diseases Clinical Research Director Prof. Dr. Atilla Soran and Turkey held under the chairmanship of the joint studies with the prestigious US scientific high was published this week in the Journal of Clinical Breast Cancer. The collaboration followed in Turkey in 41 patient's bone, lung, liver and by observing the cancer gene in cancer has spread to organs such as brain tumors have a distinct gene profile for patients in Turkey were investigated. In the study, the DNA sequence of tumor cells was examined with a special research technique developed at the University of Pittsburgh targeting 79 tumor genes and 1369 mutations. In Turkish patients, 59 different changes were found in 38 different tumor genes, 8 of which were found to be clinically important and could guide treatment. Unlike general studies in Turkish patients, it has been shown that some tumor genes can cause organ spread and long life can be achieved by detecting and suppressing these tumor genes.

Treatment protocols may vary

In our country before, Prof. Dr. With the clinical research conducted under the leadership of Atilla Soran and included in the literature as a "Turkish Study", Prof. Dr. Soran and her team showed that the chance of life was prolonged with timely surgical intervention in breast cancer patients with distant organ spread, and the 10-year life in these patients increased by 30 percent.

This newly published research supports that changes in tumor genes of Turkish patients with cancer that has spread to the distant organ may pave the way for new drugs in treatment and that survival can be achieved in much more patients in 10 years of follow-up. Prof. Dr. Atilla Soran "they found in the last 10 years in Turkey or advanced breast cancer with their work jointly with Turkey an important contribution to the world and said it changed the treatment protocols of these studies.

Short… Short… Short…

• In the USA, over 300 thousand patients in total and over 40 thousand deaths are expected due to breast cancer in 2020.
• 3.5 million women who were diagnosed and treated for breast cancer in the USA continue their lives.
• If a woman has breast cancer in her first degree relatives like her mother, sister or daughter, her risk of getting breast cancer increases twice.
• With the decrease in the use of hormone replacement therapy without indication, the rate of breast cancer has decreased by 7 percent.
• Death from breast cancer has decreased by 2 percent compared to the previous 10 years with early diagnosis and newly developed treatments.
• When diagnosed early, the 5-year survival rate increases to 99 percent, while this rate decreases to 20 percent for those who have spread to the organs late.